8FAH
 
 | | Crystal structure of SARS-CoV-2 receptor binding domain in complex with SARS-CoV-2 reactive human antibody CR3022 | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, CR3022 Fab heavy chain, CR3022 Fab light chain, ... | | 著者 | Sankhala, R.S, Jensen, J.L, Joyce, M.G. | | 登録日 | 2022-11-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-02-14 | | 実験手法 | X-RAY DIFFRACTION (4.22 Å) | | 主引用文献 | Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Structure, 32, 2024
|
|
7U8E
 | |
8SMT
 | | Crystal structure of antibody WRAIR-2134 in complex with SARS-CoV-2 receptor binding domain | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Spike protein S1, WRAIR-2134 Fab heavy chain, ... | | 著者 | Sankhala, R.S, Jensen, J.L, Joyce, M.G. | | 登録日 | 2023-04-26 | | 公開日 | 2023-06-28 | | 最終更新日 | 2024-02-14 | | 実験手法 | X-RAY DIFFRACTION (3.16 Å) | | 主引用文献 | Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Structure, 32, 2024
|
|
8SGU
 | | Crystal structure of the SARS-CoV-2 receptor binding domain | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, ... | | 著者 | Sankhala, R.S, Jensen, J.L, Joyce, M.G. | | 登録日 | 2023-04-13 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-02-14 | | 実験手法 | X-RAY DIFFRACTION (1.95 Å) | | 主引用文献 | Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Structure, 32, 2024
|
|
8SMI
 | | Crystal structure of antibody WRAIR-2123 in complex with SARS-CoV-2 receptor binding domain | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike protein S1, WRAIR-2123 Fab heavy chain, ... | | 著者 | Sankhala, R.S, Jensen, J.L, Joyce, M.G. | | 登録日 | 2023-04-26 | | 公開日 | 2023-12-13 | | 最終更新日 | 2024-02-14 | | 実験手法 | X-RAY DIFFRACTION (3.5 Å) | | 主引用文献 | Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
Structure, 32, 2024
|
|
